EP0722343A4 - Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines - Google Patents

Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines

Info

Publication number
EP0722343A4
EP0722343A4 EP94930031A EP94930031A EP0722343A4 EP 0722343 A4 EP0722343 A4 EP 0722343A4 EP 94930031 A EP94930031 A EP 94930031A EP 94930031 A EP94930031 A EP 94930031A EP 0722343 A4 EP0722343 A4 EP 0722343A4
Authority
EP
European Patent Office
Prior art keywords
cytokines
tumors
treatment
tumor cells
genes encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94930031A
Other languages
German (de)
French (fr)
Other versions
EP0722343A1 (en
Inventor
Kenneth W Culver
Charles J Link Jr
Michael R Blaese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP0722343A1 publication Critical patent/EP0722343A1/en
Publication of EP0722343A4 publication Critical patent/EP0722343A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP94930031A 1993-10-06 1994-10-04 Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines Withdrawn EP0722343A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US132708 1980-03-21
US13270893A 1993-10-06 1993-10-06
PCT/US1994/011251 WO1995009655A1 (en) 1993-10-06 1994-10-04 Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines

Publications (2)

Publication Number Publication Date
EP0722343A1 EP0722343A1 (en) 1996-07-24
EP0722343A4 true EP0722343A4 (en) 1999-12-29

Family

ID=22455246

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94930031A Withdrawn EP0722343A4 (en) 1993-10-06 1994-10-04 Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines

Country Status (4)

Country Link
EP (1) EP0722343A4 (en)
JP (1) JPH09504518A (en)
CA (1) CA2173495A1 (en)
WO (1) WO1995009655A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
IL134936A0 (en) 1997-09-10 2001-05-20 Vion Pharmaceuticals Inc Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6147177A (en) 1998-02-23 2000-11-14 The B. F. Goodrich Company Polycyclic resist compositions with increased etch resistance
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
GB9924981D0 (en) * 1999-10-21 1999-12-22 Univ Manchester Gene therapy
EP1242616A2 (en) * 1999-12-06 2002-09-25 Axxima Pharmaceuticals Aktiengesellschaft Method for identification and quantification of kinase inhibitors
JPWO2002041922A1 (en) * 2000-11-24 2004-03-25 丸山　弘樹 Method for controlling the activity of an expression product of a gene introduced into a living body
EP2338524B1 (en) 2004-08-12 2013-05-22 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
WO2008095027A2 (en) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005262A1 (en) * 1990-09-14 1992-04-02 The John Hopkins University Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
WO1993002556A1 (en) * 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993021959A1 (en) * 1992-05-01 1993-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bystander effect tumoricidal therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005262A1 (en) * 1990-09-14 1992-04-02 The John Hopkins University Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
WO1993002556A1 (en) * 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993021959A1 (en) * 1992-05-01 1993-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bystander effect tumoricidal therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LINK ET AL: "IN VIVO COMBINATION GENE THERAPY WITH THE HERPES SIMPLEX THYMIDINE KINASE (HS-TK) AND INTERLEUKIN-2 (IL-2) GENES FOR THE TREATMENT OF OVARIAN CANCER", JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT 18A, 4 January 1994 (1994-01-04) - 23 January 1994 (1994-01-23), pages 238, XP002070204 *
See also references of WO9509655A1 *

Also Published As

Publication number Publication date
WO1995009655A1 (en) 1995-04-13
EP0722343A1 (en) 1996-07-24
JPH09504518A (en) 1997-05-06
CA2173495A1 (en) 1995-04-13

Similar Documents

Publication Publication Date Title
EP0722343A4 (en) Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines
EP0963207A4 (en) Il-12 gene therapy of tumors
AU3944885A (en) DNA encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
AU3066992A (en) Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
IL80141A0 (en) Multi-level power amplifying circuitry for portable radio transceivers
CA2164088A1 (en) Plasmids suitable for gene therapy
CA2147372A1 (en) Multidrug resistance gene
AU587959B2 (en) The effect of human tumor necrosis factor and human interferon on human cancer cells and methods
ZA945012B (en) Viral vectors and their use in gene therapy
IL100908A0 (en) Invertase genes and their use
AU6786887A (en) Tumor localization and therapy
AU6879994A (en) Nucleic acid markers for rice blast resistance genes and rice blast resistance genes isolated by the use of these markers
WO1997027284A3 (en) Human rad50 and septin-2 genes and methods of use
ZA951731B (en) Genes and genetic elements aasociated with control of neoplastic transformation in mammalian cells
EP0716614A4 (en) Treatment of human tumors by genetic transformation of human tumor cells
AU2992089A (en) Acrylic acid morpholides, their production and use
AU2362795A (en) Introduction of HIV-protective genes into cells by particle-mediated gene transfer
EP0666313A3 (en) Targeting of telomerase in cancer gene therapy.
AU7665396A (en) Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
GB9311130D0 (en) Tumor metastasis gene
AU6879894A (en) Nucleic acid markers for rice blast resistance genes and rice blast resistance genes isolated by the use of these markers
ZA941422B (en) Method for inducing tumor cell death
HUP9901786A3 (en) Immuno-magnetic cell separation used in identification of genes associated with sitepreferenced cancer methastasis formation
AU4644297A (en) Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991112

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981103